<DOC>
	<DOCNO>NCT01521403</DOCNO>
	<brief_summary>The objective study determine whether set primary health care effective treat metronidazole return traveller gastrointestinal symptom B. hominis stool .</brief_summary>
	<brief_title>Is Effective Treat Patients With Blastocystis Hominis Infection ?</brief_title>
	<detailed_description>Prevalence B. hominis 30-50 % develop country . Many traveller visit develop country therefore risk infect parasite . It 's frequent traveller return develop country gastro-intestinal symptom approximately 10 % B. hominis sole parasite identified stool . Some anti-infective drug , include metronidazole , trimethoprim-sulfamethoxazole nitazoxanide , show activity B. hominis , still controversy pathogenic potential B. hominis consensus indication treatment . It hypothesise metronidazole effective placebo return traveller gastrointestinal symptom B. hominis sole intestinal parasite identify stool .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Blastocystis Infections</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>≥ 18 year Gastrointestinal symptoms 10 day B. hominis quantity least one stool specimen 3 examine No pathogenic microorganism identify Fever &gt; 37.5° bloody diarrhoea weight loss &gt; 10 % usual body weight significant decrease general condition oncological disease immune deficiency know chronic intestinal disease use antiprotozoan drug last 2 week use anticoagulant treatment antabuse pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Blastocystis hominis</keyword>
	<keyword>Metronidazole</keyword>
</DOC>